Skye Bioscience, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Skye Bioscience, Inc. (SKYE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$46.42 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-10
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$46.42K, a 145.98% decline from fiscal 2023.
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $100.96K, a 44.73% increase from fiscal 2022.
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $69.75K, a 118.92% increase from fiscal 2021.
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $31.86K, a 50.43% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | -$46.42K 10-K · filed 2026-03-10 |
| 2023-12-31 | $100.96K 10-K · filed 2025-03-20 |
| 2022-12-31 | $69.75K 10-K · filed 2024-03-22 |
| 2021-12-31 | $31.86K 10-K · filed 2023-03-31 |
| 2020-12-31 | $64.27K 10-K · filed 2022-03-28 |
| 2019-12-31 | $121.29K 10-K · filed 2021-03-02 |
| 2018-12-31 | $67.97K 10-K · filed 2020-03-23 |
| 2017-12-31 | $73.88K 10-K · filed 2019-03-14 |
| 2016-12-31 | $83.33K 10-K · filed 2018-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |